TMOD-06. HIGH INCIDENCE OF TUMORS AFTER TREATMENT WITH A DNA-ALKYLATING AGENT IN MOUSE STRAINS COMMONLY USED IN PRE-CLINICAL STUDIES

Glioblastoma (GBM) is commonly treated with the DNA-alkylating agent temozolomide (TMZ). Silencing O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation predicts response to TMZ. Oral TMZ administration also affects tissues with low MGMT expression, such as bone marrow, resultin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Irtenkauf, Susan, Hasselbach, Laura, Transou, Andrea, Poisson, Laila, Noushmehr, Houtan, Rybkin, Igor, deCarvalho, Ana
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217200/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.1119
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky